Have your say: EU AI Act consultation on high-risk systems

European Union flag ERDERA

The European Commission has opened a public consultation to gather feedback on the implementation of the AI Act’s rules concerning high-risk AI systems. The aim is to collect practical examples, clarify open questions, and inform upcoming Commission guidelines on the classification of high-risk systems and related obligations.

Under the AI Act, high-risk AI systems fall into two main categories:

  • Important for product safety under the Union’s harmonised legislation on product safety
  • Those that can significantly affect people’s health, safety, or fundamental rights in specific use cases listed in the AI Act.

The consultation also addresses responsibilities across the AI value chain, helping to define roles and accountability for all actors involved.
The Commission invites input from a wide range of stakeholders, including AI developers and providers, businesses and public sector users, academia and research organisations, civil society and citizens, regulatory and supervisory authorities.

The deadline is 18 July 2025.  Learn more.

News & Updates

You might also be interested in

European Parliament

European Parliament draft report urges a binding EU rare disease action framework

A legislative own initiative file in the Parliament’s new public health committee sets out what an EU “rare disease action framework” could look like — and why it could change how Europe measures progress for patients.
European Parliament Photograph

New European Parliament study maps options for an EU rare disease action plan

European Parliament research service assessment, published in February 2026, identifies 31 measures that could form an EU rare disease action plan, highlighting European Reference Networks and cross-border collaboration including ERDERA as drivers of EU added value.
Publicaciones (1)

EU rare disease action plan- European Added Value Assessment

This study investigates possible measures that could be taken at EU level to address these challenges. It finds significant European added value in harmonising coordination and access across the 27 Member States, mainly in terms of improved diagnostic tools and availability of medical treatment, better health outcomes, particularly lower infant mortality, and improved well-being of family members and caregivers.
Rare Disease Day 2026 visual representation

One year of ERDERA: the European alliance built to accelerate rare disease research reports first results

28 February, across Europe and beyond: one year into delivery, ERDERA is advancing towards shorten diagnostic journeys and improved therapies for people living with a rare disease.

ERDERA's

search form